NCT04402866 - TD-0903 for ALI Associated With COVID-19 | Biotech Hunter

Enrollment

235

Participants

Timeline

Start Date

June 24, 2020

Primary Completion Date

April 21, 2021

Study Completion Date

April 21, 2021

Conditions

Acute Lung Injury (ALI) Associated With COVID-19Lung Inflammation Associated With COVID-19

Interventions

DRUG

TD-0903

Study Drug to be administered by inhalation

DRUG

Placebo

Placebo to be administered by inhalation

Trial Locations (24)

11040

Theravance Biopharma, Hyde Park

12801

Theravance Biopharma Investigational Site, Glens Falls

18015

Theravance Biopharma Investigational Site, Bethlehem

18103

Theravance Biopharma Investigational Site, Allentown

20520

Theravance Biopharma Investigational Site, Turku

21105

Theravance Biopharma Investigational Site, Bucharest

33870

Theravance Biopharma Investigational Site, Sebring

43214

Theravance Biopharma Investigational Site, Columbus

59901

Theravance Biopharma Investigational Site, Kalispell

80220

Theravance Biopharma Investigational Site, Denver

91010

Theravance Biopharma Investigational Site, Duarte

98801

Theravance Biopharma Investigational Site, Wenatchee

02135

Theravance Biopharma Investigational Site, Boston

02720

Theravance Biopharma Investigational Site, Fall River

01323-001

Theravance Biopharma Investigational Site, Bela Vista

18618-686

Theravance Biopharma Investigational Site, Botucatu

95070-560

Theravance Biopharma Investigational Site, Caxias do Sul

15090-000

Theravance Biopharma Investigational Site, São José do Rio Preto

00290

Theravance Biopharma Investigational Site, Helsinki

MD-2025

Theravance Biopharma Investigational Site, Chisinau

07 400

Theravance Biopharma Investigational Site, Brovary

01 103

Theravance Biopharma Investigational Site, Kyiv

01 601

Theravance Biopharma Investigational Site, Kyiv

M23 9QZ

Theravance Biopharma Investigational Site, Manchester